2015
Heart failure: New data do not Support triple RAAS blockade
Publication
Publication
Nature Reviews Nephrology , Volume 11 - Issue 5 p. 260- 261
The SUPPORT trial evaluated the effect of adding the angiotensin-receptor blocker olmesartan to a combination of angiotensin-converting-enzyme inhibitors and ?-blockers in hypertensive patients with chronic stable heart failure. Unfortunately, this triple renin-angiotensin- aldosterone system blockade was associated with worsening of renal function and increases in cardiac events and mortality.
| Additional Metadata | |
|---|---|
| doi.org/10.1038/nrneph.2015.30, hdl.handle.net/1765/89179 | |
| Nature Reviews Nephrology | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Danser, J., & van den Meiracker, A. (2015). Heart failure: New data do not Support triple RAAS blockade. Nature Reviews Nephrology, 11(5), 260–261. doi:10.1038/nrneph.2015.30 |
|